Market Research Report
APAC Biosimilar Market, Forecast 2025
|Published by||Frost & Sullivan||Product code||602441|
|Published||Content info||160 Pages
Delivery time: 1-2 business days
|APAC Biosimilar Market, Forecast 2025|
|Published: January 10, 2018||Content info: 160 Pages||
Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth
Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan's estimate, biologic drugs worth $70-$80 billion will lose exclusivity in the next 5 years globally and APAC's contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, offer an attractive opportunity for drug development and commercialization. Moreover, these are generics-driven markets, providing a positive opportunity for biosimilars development and commercialization.
The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation. In the next 4-5 years, two-thirds of the patent expiries would be in biosimilars and specialty segments such as bio-betters that have high profit margins.
High revenue-churning blockbuster drugs are set to lose their patent protection in APAC during the forecast period and biosimilars companies are proactive in filing applications for marketing rights. In the pharmaceuticals market, there is a shift towards higher-value biological therapies, biosimilars, and specialty segments, where there is less competition despite high profit margins. With several biological drugs expected to lose patents by 2020, this segment is expected to experience an annual growth rate of more than 30.0% by 2020. Many Asian companies have biosimilars molecules under development, such as LG Life Sciences, Samsung Bioepis, and Celtrion. Cipla has already launched the biosimilar version in India in 2013, followed by Intas Pharmaceuticals in March 2015. Samsung Bioepis has also received approval for its biosimilar in South Korea in September 2015 for entracept.
The key objective of this research service is to help clients identify the major growth opportunities for biosimilars across therapeutic areas such as rheumatoid arthritis, cancer, and diabetes, and understand the key challenges in the space.